A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms: MYELODYSPLASTIC NEOPLASM

Ian M. Bouligny; Guillermo Montalban-Bravo; Koji Sasaki; Naval Daver; Elias Jabbour; Yesid Alvarado; Courtney D. DiNardo; Farhad Ravandi; Gautam Borthakur; Naveen Pemmaraju; Tapan Kadia; Lucia Masarova; Koichi Takahashi; Michael Andreeff; Alexandre Bazinet; Hui Yang; Rashmi Kanagal; Sherry Pierce; Meghan Meyer; Xuelin Huang; Guillermo Garcia-Manero

doi:10.1038/s41375-024-02457-7

A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms: MYELODYSPLASTIC NEOPLASM

Ian M. Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Naveen Pemmaraju, Tapan Kadia, Lucia Masarova, Koichi Takahashi, Michael Andreeff, Alexandre Bazinet, Hui Yang, Rashmi Kanagal, Sherry Pierce, Meghan Meyer, Xuelin HuangGuillermo Garcia-Manero

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Article number	103208
Pages (from-to)	524-528
Number of pages	5
Journal	Leukemia
Volume	39
Issue number	2
DOIs	https://doi.org/10.1038/s41375-024-02457-7
State	Published - Feb 2025

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-024-02457-7

Cite this

A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms: MYELODYSPLASTIC NEOPLASM. / Bouligny, Ian M.; Montalban-Bravo, Guillermo ; Sasaki, Koji et al.
In: Leukemia, Vol. 39, No. 2, 103208, 02.2025, p. 524-528.

Research output: Contribution to journal › Letter › peer-review

@article{dd1c9a83a7304c738fe150ff70744481,

title = "A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms: MYELODYSPLASTIC NEOPLASM",

author = "Bouligny, {Ian M.} and Guillermo Montalban-Bravo and Koji Sasaki and Naval Daver and Elias Jabbour and Yesid Alvarado and DiNardo, {Courtney D.} and Farhad Ravandi and Gautam Borthakur and Naveen Pemmaraju and Tapan Kadia and Lucia Masarova and Koichi Takahashi and Michael Andreeff and Alexandre Bazinet and Hui Yang and Rashmi Kanagal and Sherry Pierce and Meghan Meyer and Xuelin Huang and Guillermo Garcia-Manero",

year = "2025",

month = feb,

doi = "10.1038/s41375-024-02457-7",

language = "English (US)",

volume = "39",

pages = "524--528",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "2",

}

TY - JOUR

T1 - A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms

T2 - MYELODYSPLASTIC NEOPLASM

AU - Bouligny, Ian M.

AU - Montalban-Bravo, Guillermo

AU - Sasaki, Koji

AU - Daver, Naval

AU - Jabbour, Elias

AU - Alvarado, Yesid

AU - DiNardo, Courtney D.

AU - Ravandi, Farhad

AU - Borthakur, Gautam

AU - Pemmaraju, Naveen

AU - Kadia, Tapan

AU - Masarova, Lucia

AU - Takahashi, Koichi

AU - Andreeff, Michael

AU - Bazinet, Alexandre

AU - Yang, Hui

AU - Kanagal, Rashmi

AU - Pierce, Sherry

AU - Meyer, Meghan

AU - Huang, Xuelin

AU - Garcia-Manero, Guillermo

PY - 2025/2

Y1 - 2025/2

UR - http://www.scopus.com/inward/record.url?scp=85209225067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85209225067&partnerID=8YFLogxK

U2 - 10.1038/s41375-024-02457-7

DO - 10.1038/s41375-024-02457-7

M3 - Letter

C2 - 39551874

AN - SCOPUS:85209225067

SN - 0887-6924

VL - 39

SP - 524

EP - 528

JO - Leukemia

JF - Leukemia

IS - 2

M1 - 103208

ER -

A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms: MYELODYSPLASTIC NEOPLASM

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this